99mTc-BTG-N4

99mTc-BTG-N4 (also referred to as [99mTc]Tc-N4-BTG) is an investigational technetium-99m-labeled radiopharmaceutical designed for nuclear medicine imaging, specifically conventional scintigraphy and single-photon emission computed tomography (SPECT). The agent consists of a bombesin-derived ligand that targets the gastrin-releasing peptide receptor (GRPR), conjugated to an N4 chelator for stable radiolabeling with technetium-99m. GRPR is frequently overexpressed in various malignancies, including prostate cancer, where it serves as an alternative imaging target to PSMA, particularly in patients with low or absent PSMA expression. Developed and clinically evaluated by the Klinik für Nuklearmedizin at Universitätsklinikum Augsburg, 99mTc-BTG-N4 has been studied for its biodistribution, radiation dosimetry, and safety in patients with biochemical recurrence of prostate cancer, showing no adverse pharmacologic effects.

Other names

99mTc-N4-BTGtechnetium-99m-labeled bombesin/gastrin-releasing peptide receptor ligand